ETON Insider Trading

Insider Ownership Percentage: 14.89%
Insider Buying (Last 12 Months): $462,673.60
Insider Selling (Last 12 Months): $0.00

Eton Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Eton Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Eton Pharmaceuticals Share Price & Price History

Current Price: $13.02
Price Change: Price Decrease of -0.49 (-3.63%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for ETON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$13.02Closing price on 03/30/25:

Eton Pharmaceuticals Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Eton Pharmaceuticals (NASDAQ:ETON)

27.86% of Eton Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ETON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$29Mbought$7.80MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Eton Pharmaceuticals logo
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More on Eton Pharmaceuticals

Today's Range

Now: $13.02
Low: $12.83
High: $13.64

50 Day Range

MA: $15.54
Low: $13.02
High: $18.25

52 Week Range

Now: $13.02
Low: $3.03
High: $18.41

Volume

173,499 shs

Average Volume

161,360 shs

Market Capitalization

$349.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Who are the company insiders with the largest holdings of Eton Pharmaceuticals?

Eton Pharmaceuticals' top insider shareholders include:
  1. Opaleye Management Inc (Major Shareholder)
Learn More about top insider investors at Eton Pharmaceuticals.

Who are the major institutional investors of Eton Pharmaceuticals?

Eton Pharmaceuticals' top institutional shareholders include:
  1. Nantahala Capital Management LLC — 4.29%
  2. Westside Investment Management Inc. — 2.21%
  3. Mink Brook Asset Management LLC — 1.75%
  4. Cannell Capital LLC — 1.46%
  5. Parkman Healthcare Partners LLC — 1.06%
  6. Geode Capital Management LLC — 1.03%
Learn More about top institutional investors of Eton Pharmaceuticals stock.

Which major investors are selling Eton Pharmaceuticals stock?

Within the previous quarter, ETON stock was sold by these institutional investors:
  1. Acuitas Investments LLC
  2. Paradigm Capital Management Inc. NY
  3. Westside Investment Management Inc.
  4. EAM Investors LLC
  5. Bridgeway Capital Management LLC
  6. Wasatch Advisors LP
  7. Geode Capital Management LLC
  8. Essex Investment Management Co. LLC

Which major investors are buying Eton Pharmaceuticals stock?

In the previous quarter, ETON stock was acquired by institutional investors including:
  1. Mink Brook Asset Management LLC
  2. Cannell Capital LLC
  3. Connor Clark & Lunn Investment Management Ltd.
  4. Millennium Management LLC
  5. Nantahala Capital Management LLC
  6. Two Sigma Investments LP
  7. Renaissance Technologies LLC
  8. Schonfeld Strategic Advisors LLC